13,498 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Magnetar Financial LLC

Magnetar Financial LLC bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,498 shares of the company’s stock, valued at approximately $723,000.

Several other hedge funds and other institutional investors have also modified their holdings of JANX. Victory Capital Management Inc. lifted its stake in shares of Janux Therapeutics by 143.4% in the 3rd quarter. Victory Capital Management Inc. now owns 29,745 shares of the company’s stock valued at $1,351,000 after purchasing an additional 17,525 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Janux Therapeutics in the 3rd quarter valued at about $368,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares in the last quarter. Algert Global LLC acquired a new position in shares of Janux Therapeutics in the 3rd quarter valued at about $1,112,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Janux Therapeutics by 27.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock valued at $1,390,000 after purchasing an additional 6,547 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the company. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Scotiabank reduced their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Wedbush restated an “outperform” rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $92.44.

Insider Activity

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the sale, the chief executive officer now directly owns 217,054 shares in the company, valued at $12,196,264.26. This trade represents a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,002 shares of company stock worth $2,684,703. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $29.94 on Friday. Janux Therapeutics, Inc. has a one year low of $28.92 and a one year high of $71.71. The business’s 50-day simple moving average is $36.89 and its 200 day simple moving average is $46.44. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -25.59 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.